Roivant Sciences (ROIV) Cash from Operations (2020 - 2025)
Roivant Sciences (ROIV) reported Cash from Operations of 586531000.0 for Q4 2025, up 12.05% on a YoY basis from 523458044.28 in Q4 2024, and down 215.91% quarter-over-quarter from 185664000.0 in Q3 2025.
Roivant Sciences (ROIV) Cash from Operations (2020 - 2025) Analysis & Trends
Roivant Sciences has reported Cash from Operations for 6 years, with the latest figure at 586531000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 12.05% year-over-year to 586531000.0; the trailing twelve-month figure through Dec 2025 stood at 1643464000.0 (up 7.84% YoY), and the FY2026 full-year result was 750349000.0, up 10.61% from the prior year.
- Cash from Operations for Q4 2025 stood at 586531000.0, down from 185664000.0 in the prior quarter.
- The five-year high for Cash from Operations was 120596000.0 in Q3 2021, with the low at 666886000.0 in Q4 2024.
- Historically, Cash from Operations has averaged 340287466.67 across 5 years, with a median of 249932000.0 in 2023.
- Annual changes were most pronounced in 2021 — Cash from Operations plunged 187.71% — and 2025, when it jumped 30.41%.
- Roivant Sciences' Cash from Operations stood at 530260000.0 in 2021, then declined by 25.28% to 664305000.0 in 2022, then gained by 1.13% to 656811000.0 in 2023, then declined by 1.53% to 666886000.0 in 2024, then rose by 12.05% to 586531000.0 in 2025.
- The last three Cash from Operations figures came in at 586531000.0 (Q4 2025), 185664000.0 (Q3 2025), and 204383000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Roivant Sciences | 21.82 Bn | 22.59 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -586.53 Mn |
| Dec 31, 2025 | -586.53 Mn |
| Sep 30, 2025 | -185.66 Mn |
| Sep 30, 2025 | -185.66 Mn |
| Jun 30, 2025 | -204.38 Mn |
| Jun 30, 2025 | -204.38 Mn |
| Dec 31, 2024 | -666.89 Mn |
| Dec 31, 2024 | -666.89 Mn |
| Sep 30, 2024 | -266.81 Mn |
| Sep 30, 2024 | -266.81 Mn |
| Jun 30, 2024 | -192.83 Mn |
| Jun 30, 2024 | -192.83 Mn |
| Dec 31, 2023 | -656.81 Mn |
| Dec 31, 2023 | -656.81 Mn |
| Sep 30, 2023 | -196.43 Mn |
| Sep 30, 2023 | -196.43 Mn |
| Jun 30, 2023 | -249.93 Mn |
| Jun 30, 2023 | -249.93 Mn |
| Dec 31, 2022 | -664.31 Mn |
| Dec 31, 2022 | -664.31 Mn |